CO2 Gro Inc.
28.7.2021 14:32:50 CEST | ACCESS Newswire | Press release
TORONTO, ON / ACCESSWIRE / July 28, 2021 / Toronto based CO2 GRO Inc. ("GROW") (TSXV:GROW, OTCQB:BLONF, Frankfurt: 4021) is pleased to announce a commercial feasibility of a CO2 Delivery Solutions™ system with a US based floriculture greenhouse ("Client"). The Client has requested not to be named, nor the type of flower being grown or location of their greenhouse for competitive reasons.
The commercial feasibility will be conducted on a section of the greenhouse for approximately 12 months. The goals of the feasibility are to accelerate the growth of flowers to blooming in order to bring products to market sooner, as well as pathogen protection. Scientific research and field trials conducted by CO2 GRO as well as a flower commercial feasibility have demonstrated the benefits of CO2 Delivery Solutions™ technology to deliver significant improvements in flower appearance. The client has paid a fee of CAD$25,000 for the commercial feasibility.
GROW's VP Sales & Strategic Alliances, Aaron Archibald stated, "In our early days, floriculture greenhouses showed a lot of interest in our technology. However, the pandemic slowed that market for us as countries initially deemed floriculture as non-essential. We are now seeing more interest again from growers of high value flowers. Our scientific research, field trials and a commercial feasibility highlighted the value our technology provides to growers in an industry where speed to market is crucial. We plan to leverage those results with growers of various high value flowers such as roses, nursery liners and other areas of the floriculture industry where we can provide significant benefits to growers."
Visit www.co2delivery.ca for more information on CO2 Delivery Solutions™ or watch this video. To see a CO2 Delivery Solutions™ VCO2 system installation, watch this video.
About CO2 GRO Inc. (https://www.co2gro.ca/)
GROW's proprietary CO2 Delivery Solutions™ technology is revolutionizing the global 600 billion square foot protected agriculture industry (Cuesta Roble 2018). We create a saturated CO2 solution that when misted onto plants provides growers that cannot gas with CO2 the opportunity to increase plant yields by up to 30% and profits by up to 100%. Applying saturated CO2 also suppressed the development of pathogens such as E.coli and powdery mildew, helping to reduce crop losses. GROW's CO2 Delivery Solutions™ is protected by a suite of patents and patents pending.
The worldwide market for GROW's disruptive CO2 Delivery Solutions™ technology is the 50 billion square feet of greenhouses and 550 billion square feet of protected agriculture facilities (Cuesta Roble 2018). Growers can maximize revenue and profits with our systems' low fixed and variable costs and ease of systems installation.
GROW's management is rapidly expanding its international marketing partner relationships into the EU, the UK, South Africa, the Middle East, South East Asia, Mexico and Latin America as well as in its North American base.
GROW is committed to good Environment, Social and Governance (ES&G) policy and practices. We are an equal opportunity employer of choice and opportunity.
Our mission is to accelerate the growth of all value plants safely, economically, naturally and sustainably using our patented advanced CO2 Delivery Solutions™ while accreting value to our customers, stakeholders and shareholders.
Forward-Looking Statements
This press release contains statements which constitute "forward‐looking information" within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities. Forward‐ looking information is often identified by the words "may," "would," "could," "should," "will," "intend," "plan," "anticipate," "believe," "estimate," "expect" or similar expressions and include information regarding: statements regarding the future direction of the Company; the ability of the Company to successfully achieve its business and financial objectives; plans for expansion and the ability of the Company to obtain, develop and foster its business relationships; and expectations for other economic, business, and/or competitive factors. Investors are cautioned that forward‐looking information is not based on historical facts but instead reflect the Company's management's expectations, estimates or projections concerning the business of the Company's future results or events based on the opinions, assumptions and estimates that management considered reasonable at the date the statements are made. Such assumptions include but are not limited to: general business and economic conditions; the Company's ability to successfully execute its plans and intentions; the availability of financing on reasonable terms; the Company's ability to attract and retain skilled staff; market competition; the products and technology offered by the Company's competitors; and that good relationships with business partners will be maintained. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; in particular, in the ability of the Company to raise debt and equity capital in the amounts and at the costs that it expects; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; the biotechnology industry and the greenhouse growers market are highly competitive, and technical advances in the industry will impact the success of the Company, and other risks described in the Company's filings that are available at www.sedar.com. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information, please visit www.co2gro.ca or contact Michael O'Connor, Manager, Investor Relations at 604-317-6197 or michael.oconnor@co2gro.ca
SOURCE: CO2 Gro Inc.
View source version on accesswire.com:
https://www.accesswire.com/657385/CO2-GRO-Inc-Announces-a-Commercial-Feasibility-with-a-US-Floriculture-Greenhouse
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Caldwell Strengthens Life Sciences and Healthcare Practice with Addition of Dr. Christoph Themel as Partner3.2.2026 11:30:00 CET | Press release
TORONTO, ON AND LONDON, UK / ACCESS Newswire / February 3, 2026 / Retained executive search firm Caldwell (TSX:CWL)(OTCQX:CWLPF) today announced the addition of Dr. Christoph Themel as a Partner in the firm's Life Sciences and Healthcare Practice. Based in London, Dr. Themel advises boards, investors, and senior leadership teams on executive and non-executive appointments, leadership assessments, and succession planning across the pharmaceutical, biotechnology, and animal health sectors. Dr. Christoph Themel joins Caldwell as partner in the firm's Life Sciences and Healthcare Practice With more than 20 years of experience in executive search and leadership advisory, Dr. Themel is a trusted advisor to big and mid-sized pharmaceutical companies, family-owned enterprises, private equity firms, and portfolio company leadership teams across Europe, the United States, and Asia Pacific. He is particularly known for his ability to partner closely with shareholders and management teams on C-sui
AI Rises on the Finance Leadership Agenda as Cost Control Dominates 2026, New Survey Reveals3.2.2026 10:00:00 CET | Press release
MANCHESTER, UK / ACCESS Newswire / February 3, 2026 / AccessPay, the leading bank integration provider, today announced the release of its Finance Trends 2026 report, presenting the findings of its annual survey of finance leaders. In this fourth year of the report, AccessPay reveals marked sectoral differences between finance teams in financial services firms and those in corporates with regards to their priorities and attitudes to technology adoption. Key findings from the report include: 1. Finance leaders are prioritising finance efficiency and cost control Finance teams across all sectors are placing renewed emphasis on efficiency and cost control in 2026. 47% of general corporates cited this as a priority, a goal shared by 46% of financial services firms. Although cost control is a perennial concern in financial management, sluggish economic growth, rising costs, and geopolitical turmoil have brought it to the fore. Finance leaders are being pushed to do more with less, which als
Formerra and Evonik Expand Distribution Partnership for Healthcare Grades2.2.2026 15:00:00 CET | Press release
Agreement Expands Access to Evonik's CARE Brand Medical Grades in the U.S. and Canada ROMEOVILLE, ILLINOIS / ACCESS Newswire / February 2, 2026 / Formerra, a leader in performance materials distribution, today announced an expanded distribution agreement that brings Evonik's CARE brand healthcare grades into Formerra's medical portfolio. Covering the United States and Canada, the agreement creates new access points for high-performance polyamides used in essential healthcare applications. This expansion kicks off at MD&M West 2026 this week, and underscores both companies' commitment to supporting the healthcare market with high-performance materials, responsive service, and continuity of supply. It also builds on the companies' two-year partnership, which introduced Evonik's VESTAMID® and TROGAMID® families to Formerra's engineered materials lineup. With this expansion, Formerra will support Evonik healthcare grades designed for fluid handling, drug delivery, diagnostic systems, surgi
Hans Vestberg, Former Verizon Chairman and CEO, Joins Digipower X As Senior Advisor2.2.2026 13:30:00 CET | Press release
This news release constitutes a "designated news release" for the purposes of the Company's amended and restated prospectus supplement dated November 18, 2025, to its short form base shelf prospectus dated May 15, 2025. MIAMI, FL / ACCESS Newswire / February 2, 2026 / Digi Power X Inc. ("Digipower X" or the "Company") (Nasdaq:DGXX)(TSXV:DGX), a vertically integrated AI infrastructure company focused on the deployment of Tier-3 modular data centers powered by owned and controlled energy assets, today announced that Hans Vestberg, former Chairman and Chief Executive Officer of Verizon Communications, has joined the Company as a senior advisor serving on its Advisory Board to support the Company's expansion strategy. Mr. Vestberg brings more than three decades of global leadership in mission-critical infrastructure, telecommunications networks, and large-scale capital deployment. He is widely recognized for leading Verizon's first commercial 5G deployment in 2018 and for advancing nationw
Formerra to Supply Foster Medical Compounds in Europe29.1.2026 15:00:00 CET | Press release
Expanded agreement infuses Formerra's European healthcare polymer portfolio with life-saving Foster® compounds. PUTNAM, CT AND ROMEOVILLE, IL / ACCESS Newswire / January 29, 2026 / Formerra and GEON® Performance Solutions today announced an agreement that designates Formerra as the preferred distributor of Foster®, LLC medical compounds in Europe. This adds to Formerra's current distribution of these materials in North and South America, enabling Formerra to now support customers who need the same product in all regions. Following GEON's January 2025 acquisition of Foster, the agreement builds on Formerra's long-standing, global partnership with GEON for flexible and rigid PVC and filled polypropylene materials. "Bringing Foster's medical-grade portfolio to Europe strengthens our ability to support healthcare manufacturers across the region with specialized compounds and the local expertise they need to navigate complex regulatory environments," said Kelly Wessner, Vice President, Key
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
